About us
Learn more about Imperagen and meet our team
Enzymes have the potential to transform industries -from pharmaceuticals to sustainable manufacturing – but engineering them has long been a slow, complex, and unpredictable process. This scientific bottleneck has slowed innovation and adoption of enzyme-based solutions across many sectors.
Imperagen was born from a single, powerful idea to address this problem; Lowering the barrier and simplifying the adoption of enzyme technology can ONLY be realised through digitalization, intersecting computational design and laboratory automation.
By digitizing and integrating the entire process, our unified Digital Enzyme Evolution platform, dramatically accelerates enzyme development – delivering higher-performance enzymes faster and more reliably than ever before.
Founded by expert enzyme engineers and computational biologists, the company was spun out of the Manchester Institute of Biotechnology – an internationally recognized center for enzymology excellence.
With the technology now developed, the team has been joined by an experienced leadership team with a proven track record of commercial strategy & operational execution across the enzyme biotechnology and pharmaceutical industry.
The Future
Our plan is to continue to advance and scale our platform, enabling us to tackle enzyme challenges across a wide range of market sectors – from industrial applications to health and sustainability.
Headquartered in Manchester, UK – the historic cradle of the industrial revolution and a modern hub of digital innovation – Imperagen is positioned at the intersection of science and technology to drive the next bio-revolution and deliver scalable, efficient, and impactful solutions.
Meet our team
Management Team / Executive Board Members
Rob Wilson, Ph.D.
Chief Executive Officer
Rob is an experienced executive with an international background in pharmaceuticals, life sciences and enzyme technology, having held business leadership roles at Avecia, Codexis and DNA Script in the UK, US and Singapore.
Andrew Currin
Chief Scientific Officer – Co-founder
Andrew is a leading expert in the fields of directed evolution, enzymology and synthetic biology and the architect of the patented gene assembly technologies underpinning Imperagen’s automated enzyme engineering platform.
Andrew Almond
Chief Information Officer – Co-founder
Andrew is a leading biophysicist and an experienced entrepreneur, having co-founded and helped to IPO C4X Discovery in 2014, before leading the spin-out of Imperagen in 2021. He is the driving force behind Imperagen’s patented approach to AI-led design and optimisation of enzymes.
Tim Eyes, Ph.D.
Chief Product Officer – Co-founder
Tim is an experienced protein engineer with academic and Big Pharma experience spanning both enzyme and antibody technologies. He leads product development and commercial engagement for Imperagen.